The Cancer Vaccine (INTISMERAN) Records Elevated Volume Relative to Market Cap on Robinhood

Risk Overview

The current risk level for The Cancer Vaccine (INTISMERAN) is elevated, primarily due to its recent trading activity and structural characteristics. The trading pair is only 1.1 hours old, which raises concerns about its maturity and potential volatility.

INTISMERAN price chart, 68 candles to Aug 19, 2026 — Snapshot captured Aug 19, 2026 · View live chart →

Scalper risk score 68/100 Elevated

Elevated risk (68/100). The strongest contributor is pair maturity: The pair is 1.1 hours old. Most catastrophic failures happen in the first day, and there is no trading history to assess. Assessed on 6 of 8 components; liquidity lock, holder concentration unavailable.

Market readEvery price this token has traded at was set in the last 1.1 hours, so there is no prior range to measure the current one against.

Pair maturity: 1.1 hours
Volume vs liquidity: 37.3x
Liquidity depth: $54,066
Contract control: 1 concern(s)

6 of 8 components assessed · partial confidence · GoPlus

Full risk assessment and coverage for INTISMERAN →

Liquidity Assessment

The liquidity figure stands at $54,066. The liquidity is workable for small positions, but larger orders will move the price against you.

Volume Assessment

The 24-hour trading volume is reported at $2,018,772. This indicates that 24h volume is 37.3x the pool's liquidity, suggesting that the same liquidity is being turned over repeatedly, which can indicate wash trading or bot activity.

Trading Behaviour

In the last hour, there were 15,551 buy transactions and 15,422 sell transactions, resulting in a buy/sell ratio of approximately 1.01.

Risk Note

This article is not financial advice.